Enzymatica AB (publ) (EN9.F)

0.2460 +0.0090 (+3.80%) As of 09:09AM CEST. Market open.

Enzymatica AB (publ)

Ideon Science Park
Scheelevägen 19
Lund 223 70
Sweden
46 4 62 86 31 00
https://www.enzymatica.se

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Claus Egstrand	Chief Executive Officer	4.71M	N/A	1961
Ms. Therese Filmersson	CFO & Deputy CEO	1.32M	N/A	1969
Ms. Malin Richter	Director of Operations	N/A	N/A	1968
Mr. Stefan Olsson	Communication Manager	N/A	N/A	1970

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company's product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care. The company offers its products through contract organizations and partner agreements with distributors who sell the products under the ViruProtect, STADAProtect, and Bisolviral brand names. Enzymatica AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Corporate Governance

Enzymatica AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.